Diet and Parkinson's disease I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food- frequency questionnaire in a case-control study

Neurology

Volumn 47, Issue 3, 1996, Pages 636-643

  Hellenbrand, W ^a   Seidler, A ^c   Boeing, H ^b   Robra, B P ^a   Vieregge, P ^d   Nischan, P ^c   Joerg, J ^e,i   Oertel, W H ^f,i   Schneider, E ^h,i   Ulm, G ^g,i  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e Barmen Hospital   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g Paracelsus Elena Hospital   (Germany)

^h Asklepios Klinik Harburg   (Germany)

ⁱ Medical Advisory Board   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARBOHYDRATE INTAKE; CASE CONTROL STUDY; COFFEE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; FEMALE; FOOD INTAKE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAT; PARKINSON DISEASE; PRIORITY JOURNAL; VEGETABLE;

EID: 9544242732     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.47.3.636     Document Type: Article

References (68)

1. Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol 1988; 45:1350-1353.
2. Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord 1990;5:66-70.
3. Vieregge P, v Maravic C, Friedrich H-J. Life-style and dietary factors early and late in Parkinson's disease. Can J Neurol Sci 1992;19:170-173.
4. Olanow CW. A radical hypothesis for neuronal degeneration. Trends Neurosci 1993;16:439-444.
5. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
6. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.
7. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand 1991;84Suppl 36:6-15.
8. Jenner P, Dexter DT, Sian J, et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol 1992;32:S82-S87.
9. Marttila RJ, Lorentz H, Rinne UK. Oxygen toxicity protecting enzymes in Parkinson's disease. J Neurol Sci 1988;86:321-331.
10. Riederer P, Sofic E, Rausch W-D, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem 1989;52:515-520.
11. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate Superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem 1989;53:692-697.
12. Wurtman RJ, Fernstrom JD. Control of brain serotonin by the diet. Adv Neurol 1984;5:19-29.
13. Berry EM, Growdon JH, Wurtman JJ, et al. A balanced carbohydrate: protein diet in the management of Parkinson's disease. Neurology 1991;41:1295-1297.
14. Wurtman RJ, Larin F, Mostafapour S, et al. Brain catechol synthesis: control by brain tyrosine concentration. Science 1974;185:183-184.
15. Wurtman RJ, Hefti F, Melamed E. Precursor control of neurotransmitter synthesis. Pharmacol Rev 1981;32:315-335.
16. Jiménez-Jiménez FJ, Mateo D, Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control-study. Mov Disord 1992;7: 339-344.
17. Wang W, Fang X, Cheng X, et al. A case-control study on the environmental risk factors of Parkinson's disease in Tianjin, China. Neuroepidemiology 1993;12:209-218.
18. Morano A, Jiménez-Jiménez FJ, Molina JA, et al. Risk-factors for Parkinson's disease: case-control study in the province of Cáceres, Spain. Acta Neurol Scand 1994;89:164-170.
19. Koller WC. Alcohol and Parkinson's disease [abstract]. Ann Neurol 1983;13:467.
20. Lang AE, Marsden CD, Obeso JA, et al. Alcohol and Parkinson's disease. Ann Neurol 1982;12:254-256.
21. Ollat H, Parvez H, Parvez S. Alcohol and central neurotransmission. Neurochem Int 1988;13:275-300.
22. Woodward JJ, Gonzales RA. Ethanol inhibition of N-methyl-D-aspartate-stimulated endogenous dopamine release from rat striatal slices: reversal by glycine. J Neurochem 1990;54:712-715.
23. Gessa GL, Muntoni F, Collu M, et al. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985;348:201-203.
24. Mereu G, Fadda F, Gessa GL. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthetized rats. Brain Res 1984;292:63-69.
25. Nehlig A, Daval J-L, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev 1992;17:139-170.
26. Popoli P, Caporali MG, De Carolis AS. Akinesia due to catecholamine depletion in mice is prevented by caffeine. Further evidence for an involvement of adenosinergic system in the control of motility. J Pharm Pharmacol 1991;43:280-281.
27. Makino Y, Ohta S, Tachikawa O, et al. Presence of tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline in foods: compounds related to Parkinson's disease. Life Sci 1988;43:373-378.
28. Yoshida M, Niwa T, Nagatsu T. Parkinsonism in monkeys produced by chronic administration of an endogenous substance of the brain, tetrahydroisoquinoline: the behavioral and biochemical changes. Neurosci Lett 1990;119:109-113.
29. Nagatsu T, Yoshida M. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions. Neurosci Lett 1988;87:178-182.
30. Niwa T, Takeda N, Tatematsu A, et al. Migration of tetrahydroisoquinoline, a possible parkinsonian neurotoxin, into monkey brain from blood as proved by gas chromatography-mass spectroscopy. J Chromatography 1988;452:85-91.
31. Kikuchi K, Nagatsu Y, Makino Y, et al. Metabolism and penetration through blood-brain barrier of parkinsonism-related compounds. 1,2,3,4-tetrahydroisoquinoline and 1-methyl-1,2,3,4-tetrahydroisoquinoline. Drug Metab Dispos 1991;19:257-262.
32. Niwa T, Takeda N, Yoshizumi H, et al. Presence of 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline and 1,2-dimethy1-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, novel endogenous amines, in parkinsonian and normal human brains. Biochem Biophys Res Commun 1991;177:603-609.
33. Hoehn M. Age distribution of patients with Parkinsonism. J Am Geriatr Soc 1976;24:79-85.
34. Poskanzer DC, Schwab RS. Cohort analysis of Parkinson's syndrome. Evidence for a single etiology related to subclinical infection about 1920. J Chron Dis 1963;16:961-973.
35. Ravenholt RT, Foege WH. 1918 Influenza, encephalitis lethargica, parkinsonism. Lancet 1982;2:860-864.
36. Kristenssen K. Potential role of viruses in neurodegeneration. Mol Chem Neuropathol 1992;16:45-58.
37. Seidler A, Hellenbrand W, Robra BP, et al. Possible environmental, occupational and other etiologic factors for Parkinson's disease: A case-control study in Germany. Neurology 1996;46:1275-1284.
38. Hellenbrand W, Boeing H, Robra B-P, et al. Diet and Parkinson's disease II: a possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology 1996;47:644-650.
39. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathologic study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
40. Jessen RJ. Statistical survey techniques. New York: John Wiley, 1978.
41. Bohlscheid-Thomas S, Hoting J, Boeing H. Wahrendorf J. Reproducibility and validity of food group intake of a food frequency questionnaire developed for the German part of the EPIC-project. Int J Epidemiol, in press.
42. Bohlscheid-Thomas S, Hoting J, Boeing H, Wahrendorf J. Reproducibility and validity of energy and macronutrient intake of a food frequency questionnaire developed for the German part of the EPIC-project. Int J Epidemiol, in press.
43. Federal Institute for Consumer Health Protection, Germany. Bundeslebensmittelschlüssel (BLS) Version II.2, 1994.
44. Willett, W. Nutritional epidemiology. New York: Oxford University Press, 1990.
45. Breslow NE, Day NE. Statistical methods in cancer research. Volume 1. The analysis of case-control studies. Lyon: IARC Scientific Publication No. 32, International Agency for Research on Cancer, 1982.
46. Schlesselman JJ. Case-control studies. Design, conduct, analysis. Oxford: Oxford University Press, 1982.
47. Statistisches Bundesamt, ed. Statistisches Jahrbuch 1993 für die Bundesrepublik Deutschland. Wiesbaden: Wiesbadener Graphische Betriebe GmbH, 1993.
48. Jain M, Howe GR, Johnson KC, et al. Evaluation of a diet history questionnaire for epidemiologic studies. Am J Epidemiol 1980;111:212-219.
49. Godwin-Austen RB, Lee PN, Marmot MG, Stern GM. Smoking and Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:577-581.
50. Colombo G, Fadda F, Gessa GL, et al. Voluntary alcohol drinking increases brain dopamine metabolism in rats. Ann 1st Super Sanita 1990;26:95-98.
51. Harris RA, Brodie MS, Dunwiddie TV. Possible substrates of ethanol reinforcement: GABA and dopamine. Ann NY Acad Sci 1992;654:61-69.
52. Paulson GW, Dadmehr N. Is there a premorbid personality typical for Parkinson's disease? Neurology 1991;41(suppl 2): 73-76.
53. Paulson GW. Addiction of nicotine is due to high intrinsic levels of dopamine. Med Hypothyses 1992;38:206-207.
54. Vieregge P. Nicotine consumption and Parkinson's disease-does the smoke clear up? [letter] Mov Disord 1995;10:359-360.
55. Vernay D, Eschalier A, Durif F, et al. Le salsolinol, molécule endogène. Possibles implications dans l'alcoolisme, la maladie de Parkinson et la douleur. L'encéphale 1989;15:511-516.
56. Carlen PL, Lee MA, Jacob M, Livshits O. Parkinsonism provoked by alcoholism. Ann Neurol 1981;9:84-86.
57. Eisenhofer G, Szabo G, Hoffman PL. Opposite changes in turnover of noradrenaline and dopamine in the CNS of ethanol dependent mice. Neuropharmacology 1990;29:37-45.
58. Josselyn SA, Beninger RJ. Behavioural effects of intrastriatal caffeine mediated by adenosinergic modulation of dopamine. Pharmacol Biochem Behav 1991;39:97-103.
59. Bharucha NE, Stokes L, Schoenberg BS, et al. A case-control study of twin pairs discordant for Parkinson's disease: a search for environmental risk factors. Neurology 1986;36:284-288.
60. Marttila RJ, Rinne UK. Herpes simplex virus antibodies in patients with Parkinson's disease. J Neurol Sci 1978;35:375-379.
61. Elizan TS, Madden DL, Noble GR, et al. Viral antibodies in serum and CSF of parkinsonian patients and controls. Arch Neurol 1979;36:529-534.
62. Fazzini E, Fleming J, Fahn S. Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease. Mov Disord 1992;7:153-158.
63. Elizan TS, Schwartz J, Yahr MD, et al. Antibodies against arboviruses in postencephalitic and idiopathic Parkinson's disease. Arch Neurol 1978;35:257-260.
64. Kohbata S, Beaman BL. L-dopa-responsive movement disorder caused by Nocardia asteroides localized in the brains of mice. Infect Immun 1991;59:181-191.
65. Gibbs CJ, Gadjusek DC. An update on long-term in vivo and in vitro studies designed to identify a virus as the cause of amyotrophic lateral sclerosis, parkinsonism dementia, and Parkinson's disease. In: Rowland LP, ed. Human motor neuron diseases. New York: Raven Press, 1982:343-353.
66. Youdim MBH, Ben-Shachar D, Riederer P. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol 1991;31(Suppl 1):34-40.
67. Lindner E. Toxikologie der Nahrungsmittel. Stuttgart: Thieme Verlag, 1990.
68. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.